Clinical Trial Update: Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating COL7A1 gene therapy to reduce recurrence of squamous cell carcinoma in skin affected by recessive dystrophic epidermolysis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Recessive Dystrophic Epidermolysis Bullosa
• Squamous Cell Carcinoma

Drugs mentioned

• COL7A1 gene therapy (COL7A1 gene therapy)

Snippet

Sponsor: Stanford University | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING